FINWIRES · TerminalLIVE
FINWIRES

研究快訊:羅克韋爾自動化上調業績展望,軟體強勁表現推動2026財年第二季業績超預期

By

-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下:羅克韋爾自動化(韓國)公佈的2026財年第二季(9月)業績遠超預期,銷售額達22億美元(年成長12%,有機成長9%),每股盈餘為3.30美元(年成長32%),高於市場普遍預期的2.88美元。強勁的業績得益於高效的營運和關鍵業務板塊的全面需求復甦。軟體與控制業務仍為成長引擎,銷售額達6.84億美元(年增20%),營業利潤率從去年同期的30.1%大幅提升至34.9%;智慧設備業務銷售額達10億美元(年成長13%),利潤率也從17.7%提升至20.9%。 ROK將2026財年每股收益預期從11.40-12.20美元上調至12.50-13.10美元,反映出成長前景趨於穩定,市場信心增強。公司認為,倉儲自動化、資料中心、半導體和能源終端市場發展勢頭強勁,高利潤率的軟體業務將透過銷售成長和強勁的價格實現提升盈利質量,而有利的產品組合也將支撐整體盈利能力的提升。

Related Articles

Australia

Citigroup Adjusts Price Target on Marathon Petroleum to $257 From $243, Maintains Neutral Rating

Marathon Petroleum (MPC) has an average rating of overweight and mean price target of $253.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $256.58, Change: $+4.04, Percent Change: +1.60%

$MPC
Research

Research Alert: Peg Reports Strong Q1 Beat; On Track For $4.2b Capex And 7% Eps Growth In 2026

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PEG reported Q1 2026 adjusted EPS of $1.55 vs. $1.43 (+8.4% Y/Y, +8.5% vs. consensus), supported by higher PSE&G margins from regulated infrastructure investments and customer growth, partially offset by higher depreciation and interest expense. PSEG Power earnings increased due to higher realized power prices and lower O&M costs, offset by lower generation volumes. We see the company as on target for $4.2B full-year 2026 capex guidance after deploying ~$0.8B in Q1, while PEG maintained long-term targets including $24B-$28B total capex for 2026-2030 and a 6%-7.5% rate base CAGR. Management reaffirmed its 2026 EPS guidance of $4.28-$4.40, representing ~7% growth at the midpoint. Both residential electric and gas customers increased ~1% on a trailing-12-month basis, which we think reflects continued execution of the regulated investment program. Annualized dividends were increased ~6% to $2.68 for 2026. We view this as a competitive growth rate amongst Multi-Utility peers.

$PEG
Australia

Merck Completes Terns Pharmaceuticals Acquisition

Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%

$MRK$TERN